On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...

Intermittent treatment with pimecrolimus over 1 year significantly reverses corticosteroid-induced skin atrophy and ...

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age. Arcutis Biotherapeutics . July 9, 2024.

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Organon’s VTAMA ® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis. The American Academy of ...

Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch relief and clear skin for many patients in a clinical trial, without the ...

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic ...

Efficacy and Tolerability of Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Subgroup Analysis of Patients with Face/Eyelid Involvement from Phase 3 INTEGUMENT-1/2 Trials Simpson, E et al.